Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-09-26
2008-10-07
Harris, Alana M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S184100, C424S204100, C436S063000, C436S064000, C436S174000, C435S004000, C435S005000, C435S007210, C435S007230, C435S325000, C435S363000, C435S366000, C435S372000, C210S780000, C210S781000, C210S782000, C210S788000
Reexamination Certificate
active
07431932
ABSTRACT:
Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.
REFERENCES:
patent: 5514340 (1996-05-01), Lansdorp et al.
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5801029 (1998-09-01), McCormick
patent: 5837512 (1998-11-01), Rabson et al.
patent: 5840502 (1998-11-01), van Vlasselaer
patent: 5861159 (1999-01-01), Pardoll et al.
patent: 6136307 (2000-10-01), Lee et al.
patent: 6475481 (2002-11-01), Talmadge
patent: 6528057 (2003-03-01), Ambrus et al.
patent: 6596268 (2003-07-01), Coffey et al.
patent: 6649157 (2003-11-01), Coffey et al.
patent: 6994858 (2006-02-01), Morris et al.
patent: 7192580 (2007-03-01), Atkins et al.
patent: 2002/0006398 (2002-01-01), Morris et al.
patent: 2002/0037543 (2002-03-01), Atkins et al.
patent: 2003/0044384 (2003-03-01), Roberts et al.
patent: 2005/0026289 (2005-02-01), Morris et al.
patent: 2283280 (1999-02-01), None
patent: 0 451 611 (1991-10-01), None
patent: 1 344 819 (2003-09-01), None
patent: WO 94/18992 (1994-09-01), None
patent: WO 94/25627 (1994-11-01), None
patent: WO 99/08692 (1999-02-01), None
patent: WO 99/18799 (1999-04-01), None
patent: WO 99/45783 (1999-09-01), None
patent: WO 00/50051 (2000-08-01), None
patent: WO 01/35970 (2001-05-01), None
Bar-Eli, N., et al., “Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells,” J. Cancer Res. Clin. Oncol. 122(7):409-415 (1996).
Bischoff, J.R., et al., “An adenovirus mutant that replicates selectively in p53-deficient human tumor,” Science 274(5286):373-376 (1996).
Blagosklonny, M.V., and el-Deiry, W.S., “In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug,” Int. J. Cancer 67(3):386-392 (1996).
Chang, H.W., et al., “The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase.” Proc. Nat. Acad. Sci. 89(11):4825-4829 (1992).
Chang, H.W. and Jacobs, B.L., “Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA.” Virology 194(2):537-547 (1993).
Chang, H.W., et al., “Rescue of vaccinia virus lacking the E3L gene by mutants of E3L.” J. Virol. 69(10):6605-6608 (1995).
Cozzi et al., “Xenotransplantation, where do we stand?”Journal of Nephrology16:S16-S21 (2003).
Duman et al., “Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression”Nephrol. Dial. Transplant.17:892-6 (2002).
Ezzat et al., “An overview of breast cancer”Annals of Saudi Medicine17(1):10-15 (1997).
Fueyo, J., et al., “A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo,” Oncogene 19(1):2-12 (2000).
Haig, D.M., et al., “The orf virus OV20.0L gene product is involved in interferon resistance and inhibits an interferon-inducible, double-stranded RNA-dependent kinase.” Immunology 93(3):355-340 (1998).
He, B., et al., “The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1α to dephosphorylate the α subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase.” Proc. Nat. Acad. Sci. 94:843-848 (1997).
Janes et al., “Activation of the Ras signaling pathway in human breast cancer cells overexpressing erbB-2”Oncogene9(12):3601-8 (1994).
Kawagishi-Kobayashi, M., et al., “Regulation of the protein kinase PKR by the vaccinia virus pseudosubstrate inhibitor K3L is dependent on residues conserved between the K3L protein and the PKR substrate eIF2α” Mol. Cell. Biology 17(7):4146-4158 (1997).
Kennedy et al., “High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer”J. Natl. Cancer Inst.83:920-6 (1991).
Lichty, B.D., et al., Abstract “Identification of vesicular stomatitis virus as a leukemolytic agent,” Blood 96(11):213b (2000).
Marini et al., “Purging of contaminating breast cancer cells from hematopoietic stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation”Clin. Cancer Res.5:1557-68 (1999).
Nemunaitis, J., “Oncolytic viruses.” Invest. New Drugs 17(4):375-386 (1999).
Nielsen, L.L, and Maneval, D.C., “P53 tumor suppressor gene therapy for cancer,” Cancer Gene Ther. 5(1):52-63 (1998).
O'Reilly, “Allogenic bone marrow transplantation: current status and future directions”The Journal of the American Society of Hematology62:941-64 (1983).
Reichard, K.W., et al., “Newcastle disease virus selectively kills human tumor cells,” J. of Surgical Research 52(5):448-453 (1992).
Romano, P.R., et al., “Inhibition of double-stranded RNA-dependent protein kinase PKR by vaccinia virus E3: role of complex formation and the E3 N-terminal domain.” Mol. Cell. Bio. 18(12):7304-7316 (1998).
Schpall et al., “A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy”Blood90:4313-20 (1997).
Sharp, T.V., et al., “The Vaccinia virus E3L gene product interacts with both the regulatory and the substrate binding regions of PKR: implications for PKR autoregulation.” Virol. 250(2):302-315 (1998).
Snyder et al., “Posttransplant lymphoproliferative disorder following nonmyelopablative allogeneic stem cell transplantation”Am. J. Surg. Pathol.28(6):794-800 (2002).
Spyridonidis, A., et al., “Minimal residual disease in autologous hematopoietic harvests from breast cancer patients,” Ann Oncol. 9(8):821-826 (1998).
Stodjl, D.F., et al., “Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus,” Nature Medicine 6(7):821-825 (2000).
Steele, T.A., “Recent developments in the virus therapy of cancer,” Proc. Soc. Exp. Biol. Med. 223(2):118-127 (2000).
Toda, et al., “Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1”Human Gene Therapy9:2177-85 (1998).
Ueno et al., “Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer”J. Clin. Oncol.16:986-93 (1998).
Wantanabe et al., “Autologous and allogeneic transplantation with peripheral blood CD34+ cells: a pediatric experience”Haematologica84:167-76 (1999).
Wiman, K.G., “New p53-based anti-cancer therapeutic strategies,” Med. Oncol. 15(4):222-228 (1998).
Wu et al., “Bone marrow purging by attenuated multi-mutated herpes simplex virus-1”Proc. Annu. Meet. AM Soc. Clin. Oncol.16:91a, Abstract #319 (1997).
Yazaki et al., “Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1”Cancer Research55:4752-6 (1995).
Yoon, S.S., et al., “An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma,” FASEB J. 14(2):301-311 (2000).
Zorn, U., et al., “Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus,” Cancer Biotherapy 9(3):225-235 (1994).
Armstrong, G.D., et al. (1984). Studies on reovirus receptors of L cells: virus binding characteristics and comparison with reovirus receptors of erythrocytes. Virology. 138(1):37-48.
Bashey, A., et al. (1994). Proliferative but not nonproliferative responses to granulocyte colony-stimulating factor
Coffey Matthew C.
Morris Donald
Thompson Bradley G.
Fish & Richardson P.C.
Harris Alana M.
Oncolytics Biotech Inc.
LandOfFree
Reovirus clearance of ras-mediated neoplastic cells from... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reovirus clearance of ras-mediated neoplastic cells from..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reovirus clearance of ras-mediated neoplastic cells from... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4013817